Search Results for: GNC Toggle Comment Threads | Keyboard Shortcuts

GNC Stock News | GNC Stock Tags | GNC Stock Financials | GNC StockChart is Delayed

  • investorsocialnetwork

    Zitrof 6:03 pm on September 23, 2018 Permalink | Reply
    Tags: , , FTK, , , , JCP   

    Watchlist 9/24

    #ACAD for continuation
    #ADMP into the gap to 3.50
    #FTK into gap to 2.80, 3+ with volume
    #GNC over 4, want to get into China market
    #IGC might be a short entry if weakness
    #JCP is in gap, to 2.40 – pretty heavy and probably slow.
    #HMNY might be setting up to give an awesome short
    Some of the Cannabis plays might be shorts, dependent on news and talk

  • investorsocialnetwork

    Zitrof 8:32 pm on September 16, 2018 Permalink | Reply
    Tags: ABUs, , , ATI, BLPH, , , , , , , , HDP, , , , , SSC, ,   

    #MYSZ – Either direction
    #LBRT might want some 21.60 action
    #HDP might be a short, CEO selling stock, near 5 year high.
    #AMD – Either ways always gives nice day trades.
    Watching Cannabis stocks, #TLRY, #CGC, #CRON, #CANN, #APHQF
    #TNDM for move over 50 or short
    #SSC if it wants to go back to test high 5.60
    #FEYE if green watch to over 17.5
    #JMEI, I just like this one
    #CVM, let’s see where it wants to go
    #FNJN for a curl of the lows here
    #ABUs, had interesting close, watch
    #LBRT, watch for 21.6
    #PI, just watching for entry (either)
    #GNC, Probably my favorite long play, room to over 4
    #BLPH, looks like it want to travel through the gap.
    #ATI, watching

  • investorsocialnetwork

    Zitrof 7:57 pm on September 13, 2018 Permalink | Reply
    Tags: , , , CZR, , EVH, EVRI, GBTC, , , LEJU, MARA, , PDD, RIGL, SESN, SRAX, SSKN, , TYME, VSI   

    9/14 Watchlist:
    #LEJU closed strong and over 52 week highs, could continue.
    #PDD is recent IPO, lately it’s been a thing. Cold get some more momentum (either direction)
    #GNC if it can get this deal done and get into China, it’s huge for company
    #EVRI another one closing at high of year, and could want more.
    #SRAX could get interesting tomorrow.
    #BLPH looks like it wants to travel up in that gap.
    #SSKN could want more, another 52 week high
    #TYME strong close, could want to run tomorrow.
    #GBTC if the bitcoins want to heat back up, this could move along with (#DPW, #MARA, #CNET, #SRAX)
    #TNDM it obviously wants 54 or more
    #NIHD let see if it wants over $6
    #BSTI another online ads company, maybe it’s a new theme coming.
    #RIGL pulled back and back back up, has insider buys.
    Finviz Screener:

  • investorsocialnetwork

    Zitrof 12:45 pm on June 7, 2018 Permalink | Reply

    VRX Biotech Catalyst 

    VRX, Valeant Pharmaceuticals International, Inc. – has an upcoming PDUFA date June 18, 2018 for IDP-118 Psoriasis

    FDA accepted the New Drug Application (NDA) for IDP-118 (halobetasol propionate and tazarotene) lotion, an investigational topical treatment for plaque psoriasis. The PDUFA action date is June 18, 2018. If approved, IDP-118 will be the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene in one formulation for the treatment of plaque psoriasis in adult patients, allowing for a potentially expanded duration of use.

    Nice amount of Insider ownership


  • investorsocialnetwork

    Zitrof 12:30 pm on June 7, 2018 Permalink | Reply

    ALT Biotech Catalyst 

    ALT – Altimmune, Inc. has three upcoming catalyst. 2 catalyst in 3Q and 1 in 4Q of 2018, and plenty of insider buying. #ALT

    NASOSHIELD, Anthrax vaccine – has Phase 1 data due early 3Q 2018
    NasoShield is based on RespirVec technology to provide protection following a single intranasal administration as opposed to multiple injections. Based on head-to-head results from studies performed in gold-standard preclinical models, NasoShield provided more rapid and consistent protection when compared to the currently approved anthrax vaccine, both potential key advantages for presumed use in a bioterrorism emergency.

    NasoVAX, Flu vaccine – Phase 2 additional data due 3Q 2018
    NasoVAX is based on our RespirVec platform, which mobilizes the immune system in ways that conventional vaccines cannot by eliciting a multifaceted response that engages the innate, cellular and mucosal immune systems. In preclinical studies, a single dose of NasoVAX provided complete protection against a lethal flu challenge within days of administration.

    My personal opinion is that the company needs $, but no open effect forms and seems like a lot of insider ownership. Could move up and squeeze with heavy shorts.

    ALT SEC Filings:

    • investorsocialnetwork

      investorsocialnetwork 12:41 pm on June 7, 2018 Permalink | Reply

      I bought in @ .66 for longer run, looking to go over $1. Depending on further DD might hold a little longer and will consider holding through announcement.

    • investorsocialnetwork

      investorsocialnetwork 8:13 am on July 11, 2018 Permalink | Reply

      Director has purchased in the high $1, and low $2’s. He has not sold anything…

compose new post
next post/next comment
previous post/previous comment
show/hide comments
go to top
go to login
show/hide help
shift + esc